saquinavir + nelfinavir + nucleoside reverse transcriptase inhibitor

A combination therapy for **HIV-1 infection** consisting of the protease inhibitors **saquinavir** and **nelfinavir**, plus a **nucleoside reverse transcriptase inhibitor (NRTI)**. This combination targets the HIV lifecycle at two critical points: inhibiting viral protease to prevent maturation of infectious virions (saquinavir, nelfinavir) and blocking reverse transcription of viral RNA into DNA (NRTI). Used in antiretroviral regimens, especially as salvage therapy after resistance or failure with other protease inhibitors. There is clinical evidence of increased plasma drug levels and virological efficacy with this combination, though it is not a standard fixed-dose combination with a unique brand name[4][1].